Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a multi center two-stage, two-arm, open label phase II study of venetoclax in
combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex
vivo venetoclax sensitivity screening. This study will characterize the usability of ex vivo
drug sensitivity testing for patient selection for selecting the responsive patients for
venetoclax therapy. The exploratory study will aim to find novel combinations for overcoming
resistance as well as finding/validating biomarkers for both sensitivity and resistance.